Citations

Showing 10 of 108083 citations.

Group B Streptococcus does not translocate the gut epithelium of neonatal mice.
Harlow, Olivia S., Greenfield, Kara G , Knoop, Kathryn A.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 208 | Issue: Supplement_1 | Pages: 59.18-59.18

10.4049/jimmunol.208.supp.59.18 Get It

Abstract Neonatal sepsis remains a leading cause of death in preterm and low-birthweight infants and can be separated into two groups: early-onset sepsis (EOS) and late-onset sepsis (LOS). Previous studies have shown that LOS can result from translocation of enteric bacteria across the intestinal epithelium, resulting in bloodstream infection. Through metagenomic sequencing we have observed, unsurprisingly, potential sepsis-causing organisms such as Escherichia coli, Staphylococcus aureus, Enterobacter cloacae, and Group B Streptococcus (GBS) in the stool of neonatal intensive care unit patients. Our previous work has shown E. coli can disseminate from the intestines via goblet cells in a model of LOS, but how other bacterial pathogens disseminate remains unclear. GBS is often associated with EOS following in utero infections and vertical transmission from the mother during pregnancy and delivery. However, the ability of gut-residing GBS to cause sepsis in a murine model of LOS is still unknown. Here we infected five-day-old mice by oral gavage with different strains of GBS, but we did not observe GBS translocating the intestinal epithelium in the pups, unlike E. coli. We next induced EOS in newborn mice by vaginally inoculating pregnant mice to assess GBS dissemination and compare the EOS model to our LOS model. After in utero infection, most pups were intestinally colonized with GBS and, interestingly, only pups with GBS colonies in the lungs had systemic GBS infections. This data suggests neonates are at risk of GBS infection in utero, but not following delivery, even if GBS colonizes the neonatal intestine. This work could elucidate the pathogenesis of EOS as compared to LOS, leading to a deeper understanding of modes of GBS transmission. Supported by NIH: DK122187
Ablation of immunity to Amblyomma americanum by anti-basophil serum: cooperation between basophils and eosinophils in expression of immunity to ectoparasites (ticks) in guinea pigs.
Galli, SJ, Gleich, Gerald J. , Askenase, Philip W., Brown, S J

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 129 | Issue: 2 | Pages: 790-796

10.4049/jimmunol.129.2.790 Get It

Abstract Basophils infiltrate the skin and other tissues as part of T lymphocyte and/or antibody-mediated immune responses to certain protein antigens, viruses, tumors, and parasites. Although basophils may comprise a significant fraction of leukocytes in these reactions, their precise role has been poorly understood. Guinea pigs expressing acquired immunity to the tick Amblyomma americanum develop basophil- and eosinophil-rich cutaneous inflammatory responses at tick feeding sites, and tick rejection is associated with extensive local basophil degranulation. We report that a specific anti-basophil serum (ABS) eliminate basophils at tick feeding sites and abolished immunity to A. americanum. ABS does not react with eosinophils and did not reduce blood or bone marrow eosinophils; however, ABS-treated animals had diminished eosinophils at tick feeding sites, perhaps because these sites were deficient in basophil-derived eosinophil-chemotactic factors. AES treatment markedly reduced feeding site eosinophils, did not affect basophil levels, and partially impaired tick resistance. Taken together, our experiments suggest cooperation between basophils and eosinophils in the expression of immunity to ticks in guinea pigs.
Comprehensive review: Frailty in pancreas transplant candidates and recipients
Parsons, Ronald F. , Tantisattamo, Ekamol , Cheungpasitporn, Wisit , Basu, Arpita , Lu, Yee , Lentine, Krista L. , Woodside, Kenneth J. , Singh, Neeraj , Scalea, Joseph R. , Alhamad, Tarek , Rivera, Franco H. Cabeza , Parajuli, Sandesh , Pavlakis, Martha , Cooper, Matthew , Scalea, Joseph , Dunn, Ty B , Cabeza Rivera, Franco H , Parajuli, Sandesh , Pavlakis, Martha , Cooper, Matthew , Cheungpasitporn, Wisit , Basu, Arpita , Tantisattamo, Ekamol , Woodside, Kenneth , Alhamad, Tarek , Lu, Yee

Mayo Clinic

Clinical Transplantation | January 2, 2023 | Volume: 37 | Issue: 2 | Pages: No page available

10.1111/ctr.14899 | PMID 36591953 Get It

AbstractWell‐selected patients with kidney disease and diabetes mellitus who undergo simultaneous kidney‐pancreas transplantation often experience dramatic improvements in quality of life and long‐term survival compared to those who remain on medical therapy. Over the past several years the importance of frailty in the pancreas transplant candidate and recipient populations has grown. More patients with advanced age have entered the waitlist, and complications from prolonged diabetes, even in younger patients, have created increased evidence of risk for frailty. Given these concerns, and the broad challenges facing pancreas transplantation volumes overall, we generated this review to help establish the impact and implications. We summarize the interplay of immunological factors, aging, environmental factors, diabetes mellitus, and chronic kidney disease that put these patients at risk for frailty. We discuss its measurement and recommend a combination of two instruments (both well‐validated and one entirely objective). We describe the outcomes for patients before and after pancreas transplantation who may have frailty, and what interventions can be taken to mitigate its effects. Broader investigation into frailty in the pancreas transplant population is needed to better understand how to select patients for pancreas transplantation and to how manage its consequences thereafter.
Tracing the evolution of H-2 D region genes using sequences associated with a repetitive element.
Duran, L W, Pease, Larry R.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 141 | Issue: 1 | Pages: 295-301

10.4049/jimmunol.141.1.295 Get It

Abstract The class I genes in the murine MHC are genetically divided into the K, D, Qa, and T1a region subfamilies. These genes presumably arose by duplication from a common class I ancestor. Oligonucleotide probes specific for sequences associated with a moderately repetitive B2 SINE element, which is inserted into the 3' untranslated region of the H-2D and H-2L genes, were used to examine the evolutionary relationship between these classically defined D region genes (H-2D and H-2L) and the other members of the class I gene family. Hybridization analyses of recombinant cosmid and genomic DNA indicated that the D region genes separated genetically from the other members of the class I gene family 12 to 14 million years ago. The evidence suggests that during this time frame the chromosomal segment harboring the characteristic insertion became fixed in the ancestral population which gave rise to Mus domesticus. Previous studies have shown that the number of genes present in the Qa and T1a regions varies among inbred strains and among laboratory stocks of wild mice derived from more distant species on the genus Mus. No evidence was found in this study to support the hypothesis that variation in class I gene number is the result of recent duplications of the functionally defined class I genes of the D region, H-2D and H-2L.
Epidemiology of Lateral Ligament Complex Tears of the Ankle in National Collegiate Athletic Association (NCAA) Sports: 2014-15 Through 2018-19
Moffit, Reagan E. , Boltz, Adrian J. , Alexander, Andrew , Robison, Hannah J., Kerr, Zachary Y. , Collins, Christy L. , Alexander, Andrew S, Kerr, Zachary Yukio , Alexander, Andrew S , Chandran, Avinash S. , Lempke, Alexandra F. DeJong , Wikstrom, Erik A.

Mayo Clinic

The American Journal of Sports Medicine | January 2, 2023 | Volume: 51 | Issue: 1 | Pages: 169-178

10.1177/03635465221138281 | PMID 36592020 Get It

Background: Epidemiological studies of lateral ankle sprains in NCAA sports are important in appraising the burden of this injury and informing prevention efforts. Purpose: To describe the epidemiology of lateral ankle sprains in NCAA sports during the 2014-15 through 2018-19 seasons. Study Design: Descriptive epidemiology study. Methods: Injury and exposure information collected within the NCAA Injury Surveillance Program (ISP) were examined. Counts, rates, and proportions of lateral ankle sprains were used to describe injury incidence by sport, event type (practices, competitions), season segment (preseason, regular season, postseason), injury mechanism (player contact, noncontact, and surface contact, injury history (new, recurrent), and time loss (time loss [≥1 day], non–time loss). Injury rate ratios (IRRs) were used to examine differential injury rates, and injury proportion ratios (IPRs) were used to examine differential distributions. Results: A total of 3910 lateral ankle sprains were reported (4.61 per 10,000 athlete exposures) during the study period, and the overall rate was highest in men’s basketball (11.82 per 10,000 athlete exposures). The competition-related injury rate was higher than the practice-related rate (IRR, 3.24; 95% CI, 3.04-3.45), and across season segments, the overall rate was highest in preseason (4.99 per 10,000 athlete exposures). Lateral ankle sprains were most often attributed to player-contact mechanisms in men’s (43.2%) and women’s sports (35.1%), although injuries were more prevalently attributed to player contact in men’s than in women’s sports (IPR, 1.23; 95% CI, 1.13-1.34). Overall, 49.7% of all lateral ankle sprains were time loss injuries. Conclusions: The findings of this study are consistent with previous epidemiological investigations of lateral ankle sprains among NCAA athletes. Results offer additional context on differential injury mechanisms between men’s and women’s sports and on injury risk across the competitive season. Future research may examine the effectiveness of deploying injury prevention programs before the start of a season.
The treatment of functional dyspepsia: present and future
Lacy, Brian E. , Chase, R. Christopher , Cangemi, David J. , Chase, R Christopher

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | January 2, 2023 | Volume: 17 | Issue: 1 | Pages: 9-20

10.1080/17474124.2023.2162877 | PMID 36588474 Get It

Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study
Hess, Brian , Giri, Anshu , Park, Yeonhee , Patel, Krina K. , Link, Brian K. , Nowakowski, Grzegorz S. , Maliske, Seth , Chávez, Julio C. , Hill, Brian T. , Garcia, Alex, Maddocks, Kami J. , Wagner‐Johnston, Nina D. , Messmer, Marcus R., Watkins, Marcus P. , Alderuccio, Juan Pablo , Lossos, Izidore S., Nathan, Sunita , Portell, Craig A. , Ayers, Emily C. , Fortin, Sonia, Chavez, Julio C , Watkins, Marcus , Alderuccio, Juan Pablo , De La Fuente, Macarena , Landsburg, Daniel J , Castillo, Jorge J , Link, Brian K , Portell, Craig A , Fortin, Sonia, Saeed, Hayder , Hanel, Walter G. , Messmer, Marcus , Kahl, Brad S. , Lossos, Izidore S. , Orellana‐Noia, Victor M. , Landsburg, Daniel J. , Castillo, Jorge J.

Mayo Clinic

American Journal of Hematology | January 2, 2023 | Volume: 98 | Issue: 2 | Pages: 300-308

10.1002/ajh.26784 | PMID 36588409 Get It

AbstractPlasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course is characterized by high relapse rates and a poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, a specific review of limited stage (LS) PBL patients is not available to evaluate outcomes and justify treatment recommendations. We performed a retrospective review of LS PBL cases to provide insight into this rare disease. Our cohort consisted of 80 stage I or II PBL patients from 13 US academic centers. With a median follow up of 34 months (1–196), the 3‐year progression‐free survival (PFS) and overall survival (OS) of the entire cohort were 72% (95% CI 62, 83) and 79% (95% CI 70, 89), respectively. The 3‐year PFS and OS of patients treated with frontline chemotherapy alone was 65% (95% CI 50, 84) and 71% (95% CI 56, 89), respectively, compared to 85% (95% CI 72, 100) and 96% (95% CI 89, 100), respectively, in patients treated with combined frontline chemotherapy with radiation consolidation. Our data demonstrate favorable outcomes in LS PBL with no improvements in outcome from aggressive frontline treatment including Hyper‐CVAD or auto‐SCT consolidation. Multivariate regression analysis (MRA) demonstrated improved PFS for patients receiving EPOCH based frontline therapy versus CHOP (HR: 0.23; p = 0.029). Frontline chemotherapy followed by radiation consolidation versus chemotherapy alone appeared to be associated with improved relapse and survival outcomes but did not show statistical significance in MRA.
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
Gertz, Morie A. , Gertz, Morie A

Mayo Clinic

American Journal of Hematology | January 2, 2023 | Volume: 98 | Issue: 2 | Pages: 348-358

10.1002/ajh.26796 | PMID 36588395 Get It

AbstractDisease OverviewWaldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity.DiagnosisPresence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in most IgM MGUS patients. MYD88 is not required for the diagnosis.Risk StratificationAge, hemoglobin level, platelet count, β2 microglobulin, LDH, and monoclonal IgM concentrations are characteristics that are predictive of outcomes.Risk‐Adapted TherapyNot all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or a BTK inhibitor. The preferred Mayo Clinic induction is either rituximab and bendamustine (without rituximab maintenance) or zanubrutinib.Management of Refractory DiseaseBortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection.
A Systematic Review and Meta-Analysis of Posttransplant Anemia With Overall Mortality and Cardiovascular Outcomes Among Kidney Transplant Recipients
Mekraksakit, Poemlarp , Leelaviwat, Natnicha , Duangkham, Samapon, Peña, Camilo , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Mekraksakit, Poemlarp , Benjanuwattra, Juthipong , Rio‐Pertuz, Gaspar Del , Thongprayoon, Charat , Kewcharoen, Jakrin , Boonpheng, Boonphiphop

Mayo Clinic

Progress in Transplantation | January 2, 2023 | Volume: 33 | Issue: 1 | Pages: 78-89

10.1177/15269248221145046 | PMID 36591924 Get It

Introduction: Posttransplant anemia is a common finding after kidney transplantation. A previous meta-analysis reported an association between anemia and graft loss. However, data on cardiovascular outcomes have not yet been reported. Objective: We conducted an updated meta-analysis to examine the association between posttransplant anemia and outcomes after transplantation including cardiovascular mortality in adult kidney transplant recipients. Methods: We comprehensively searched the databases of MEDLINE and EMBASE from inception to November 2021. Data from each study were combined using the random-effects model. Generic inverse variance method of DerSimonian and Laird was employed to calculate the risk ratios and 95% CIs. Results: Seventeen studies from August 2006 to April 2019 were included (16 463 kidney transplantation recipients). Posttransplant anemia was associated with overall mortality (pooled risk ratio = 1.72 [1.39, 2.13], I 2 = 56%), graft loss (pooled risk ratio = 2.28 [1.77, 2.93], I 2 = 94%), cardiovascular death (pooled risk ratio = 2.06 [1.35, 3.16], I 2 = 0%), and cardiovascular events (pooled risk ratio = 1.33 [1.10, 1.61], I 2 = 0%). Early anemia (≤6 months), compared with late anemia (>6 months), has higher risk of overall mortality and graft loss with a pooled risk ratio of 2.63 (95% CI 1.79-3.86; I 2 = 0%) and 2.96 (95% CI 2.29-3.82; I 2 = 0%), respectively. Discussion: In addition to increased risk of graft loss, our updated meta-analysis demonstrated that posttransplant anemia was significantly associated with poor outcomes after kidney transplantation including overall mortality, graft loss, cardiovascular death, and cardiovascular events. Future studies are required to assess the effects of treatment strategies for posttransplant anemia on posttransplant outcomes including cardiovascular mortality.
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience
Chohan, Karan , Vallumsetla, Nishanth, King, Rebecca L. , He, Rong , Gonsalves, Wilson I. , Inwards, David J. , Witzig, Thomas E. , Swaika, Abhisek, Reeder, Craig B. , Lacy, Martha Q. , Kumar, Shaji , Kyle, Robert A. , Ansell, Stephen M. , Kapoor, Prashant , Witzig, T.E. , Chohan, Karan L , Paludo, Jonas , He, Rong , Gonsalves, Wilson , Inwards, David J , Jain, Tania , Leung, Nelson , Ailawadhi, Sikander , Rajkumar, S Vincent , Kumar, Shaji K , Gertz, Morie A , Ansell, Stephen M , Paludo, Jonas , Larson, Dirk R. , Jain, Tania , Leung, Nelson , Ailawadhi, Sikander , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | January 2, 2023 | Volume: 98 | Issue: 3 | Pages: 432-439

10.1002/ajh.26807 | PMID 36588384 Get It

AbstractWaldenström macroglobulinemia (WM) is a rare, indolent lymphoma, that predominately affects the elderly. We report the outcomes of young WM patients, evaluated over five decades, compared to their older counterparts, matched for the time of diagnosis. Between January 1, 1960 and October 31, 2013, 140 (11.8%) WM patients were ≤50 years of age at diagnosis in our database, and their estimated 10‐year overall survival (OS) was 74%, with death attributable to WM in a higher proportion of patients compared to their older (≥65 years) counterparts (91% vs. 58%, p = .0001). Young patients were grouped into three cohorts based on the timing of the initiation of therapy: Group 1 (1960–1977, n = 12), Group 2 (1978–1995, n = 48), and Group 3 (1996–2013, n = 74). Among young patients, there was no disease‐specific survival (DSS) difference across the three periods, [median DSS at 13 years (95% CI 5–23), 16 years (95% CI 14–22), and 15 years (95% CI 10‐NR; p = .41), respectively]. However, DSS for the older cohort incrementally improved (Group 1, median 5.2 years, Group 2: 9.6 years, Group 3: 12 years; p = .05) over these periods. The estimated average years‐of‐life lost for the young cohort was 11.2 years from diagnosis, based on the expected survival for a normal age‐ and sex‐matched population. Despite a protracted disease course, nearly all young patients succumb to their disease. In contrast to the improved survival of the elderly patient population, the evolving treatment strategies in WM have not impacted the outcome of young patients; however, the impact of Bruton tyrosine kinase inhibitors on this unique patient population remains to be determined.